Table III.
Age-adjusted incidence rates and incidence rate ratios of marginal zone lymphoma according to site and calendar year of diagnosis, SEER-18, 2001–2009*
| 2001–2005 | 2006-–2009 | (2006–2009)-to-(2001–2005) | ||||
|---|---|---|---|---|---|---|
| n | IR | n | IR | IRR | (95% CI) | |
| All sites | 6,679 | 17.4 | 6,417 | 19.3 | 1.10 | (1.07–1.14)† |
| All nodal MZL | 1,958 | 5.1 | 2,123 | 6.4 | 1.25 | (1.17–1.33)† |
| All extranodal MZL | 4,681 | 12.2 | 4,140 | 12.4 | 1.02 | (0.97–1.06) |
| Oral cavity/oropharynx | ||||||
| HPV-related sites | 54 | 0.1 | 52 | 0.2 | 1.11 | (0.74–1.66) |
| HPV-unrelated sites | 54 | 0.1 | 35 | 0.1 | 0.75 | (0.47–1.17) |
| Salivary glands | 349 | 0.9 | 289 | 0.9 | 0.96 | (0.82–1.13) |
| Nasopharynx | 40 | 0.1 | 23 | 0.1 | 0.66 | (0.38–1.14) |
| Stomach | 1,552 | 4.1 | 1,150 | 3.5 | 0.85 | (0.79–0.92)† |
| Small intestine | 135 | 0.3 | 123 | 0.4 | 1.07 | (0.83–1.37) |
| Colon/rectum | 203 | 0.5 | 196 | 0.6 | 1.09 | (0.89–1.33) |
| Lung | 336 | 0.9 | 344 | 1.0 | 1.18 | (1.01–1.38)† |
| Spleen | 593 | 1.6 | 532 | 1.6 | 1.03 | (0.91–1.16) |
| Skin | 309 | 0.8 | 383 | 1.1 | 1.43 | (1.23–1.67)† |
| Soft tissue, including heart | 103 | 0.3 | 67 | 0.2 | 0.72 | (0.52–0.99)† |
| Female breast | 137 | 0.7 | 115 | 0.6 | 0.95 | (0.74–1.23) |
| Kidney/renal pelvis | 18 | 0.05 | 33 | 0.1 | 2.16 | (1.18–4.09)† |
| Bladder | 17 | 0.05 | 23 | 0.1 | 1.53 | (0.78–3.05) |
| Eye/adnexa | 521 | 1.4 | 505 | 1.5 | 1.12 | (0.99–1.27) |
| Thyroid | 78 | 0.2 | 96 | 0.3 | 1.42 | (1.04–1.95)† |
Abbreviations: SEER-18, 18 cancer registry areas of the Surveillance, Epidemiology and End Results Program; n, number; IR, incidence rate; IRR, incidence rate ratio; CI, confidence interval; MZL, marginal zone lymphoma; HPV, human papillomavirus.
*
All incidence rates are age-adjusted to the 2000 US standard population and expressed per 1,000,000 person-years. Incidence rate ratios are based on unrounded rates.
†
95% CI excludes 1.00 (based on unrounded upper and lower CI), and IRR is significant (P<0.05).